Your embedded strategic partner
in early-stage biotech
About BioProspero
scientifically grounded.
Led by a PhD-trained biotech strategist with operating experience from startup through IPO. Every recommendation is rooted in scientific rigor and a deep understanding of early-stage biotech.
embedded, not external.
BioProspero works as an extension of your team — from corporate strategy to operational support and program execution. Engagements range from targeted projects to ongoing embedded partnerships, structured around your priorities and stage.
flexible by design.
Senior strategic leadership without full-time overhead. BioProspero scales to fit — whether you need a single embedded strategist or a coordinated team spanning program management, technical strategy, and specialist support. Every engagement is tailored to your goals, timelines, and stage.
Client Engagements
BioProspero partners with Series A through clinical-stage biotech companies as an embedded extension of each client's team — working shoulder-to-shoulder with founders and leadership across the decisions, milestones, and inflection points that define early-stage growth.
-
Serve as fractional Chief Operating Officer or Chief Business Officer for companies seeking senior strategic leadership within a lean operating model.
-
Develop corporate strategy and investor-facing materials for companies navigating fundraising rounds, clinical data readouts, and partnership discussions.
-
Drive program leadership for preclinical through Phase 2 assets, aligning milestones, budgets, and cross-functional teams across scientific, clinical, and regulatory workstreams.
-
Synthesize scientific rationale, competitive landscape, patient population data, and development feasibility into actionable R&D investment recommendations. Evaluate indication expansion opportunities integrating epidemiology, competitive intelligence, payor and regulatory pathway analysis.
-
Conduct rigorous scientific due diligence and portfolio assessments spanning multiple modalities and therapeutic areas including oncology, immunology, neuropsychiatry, and rare disease.
Stephanie Duncanson, PhD
Founder & CEO
Stephanie Duncanson, PhD, founded BioProspero Partners after nearly a decade in biotech operating roles — most recently as Vice President of Corporate Strategy & Business Development at a clinical-stage immunotherapy company where she helped grow the organization through Series A, Series B, and IPO. She built the company’s strategy, business development, and project management functions from the ground up as it scaled from less than a dozen to over 100 employees.
Previously a strategy consultant at a top-tier life sciences advisory firm, Stephanie brings deep expertise in portfolio strategy, pipeline prioritization, clinical development strategy, and program management across therapeutic areas including oncology, immunology, neuropsychiatry, and rare disease.
PhD in Bioengineering from Georgia Institute of Technology, with bench research in cell-based therapies and regenerative medicine. NIH Cell & Tissue Engineering Fellow. BS in Chemical Engineering from Northeastern University.
What’s in a name?
We are BioProspero Partners. "Bio" reflects our roots in biotechnology. "Prospero" draws from Shakespeare's The Tempest — a wise figure who uses knowledge to orchestrate positive change. “Partners” to emphasize our belief that your success is our success. At BioProspero, we believe in the transformative potential of biotechnology to address real challenges for patients and communities. Our name reflects that mission: guiding emerging biotech companies toward prosperity through rigorous science, ethical practice, and hands-on partnership.